NeuroSense, QuantalX partner in early detection of neurodegenerative diseases

NeuroSense and QuantalX Neuroscience, developer of Delphi-MD, a clinically objective neurodiagnostic medical device, announced a collaboration to improve early diagnosis and treatment of neurodegenerative diseases. The NeuroSense-QuantalX collaboration comes following NeuroSense’s recent report on new biomarker data in Alzheimer’s disease and its plans to initiate a Phase 2 AD clinical trial in the first half of 2023. Delphi-MD is expected to provide multiple clinically objective and accurate measurements of brain function in a safe and simple manner in NeuroSense’s upcoming AD Phase 2 clinical trial. In addition, the companies agreed that QuantalX’s Delphi-MD will be used for early diagnosis and ongoing monitoring of trial participants in NeuroSense’s planned future pivotal Phase 3 efficacy trial of PrimeC in people living with amyotrophic lateral sclerosis, pending the successful conclusion of its ALS Phase 2b trial.